Alteon Inc.

Alteon is a leader in the discovery and development of novel pharmaceuticals for the treatment of pathologies of aging and diabetes, based on reversing or slowing a fundamental pathological process caused by protein-glucose complexes called Advanced Glycosylation End-products (A.G.E.s). The formation and crosslinking of A.G.E.s is an inevitable part of the aging process that leads to a loss of flexibility and function in body tissues, organs and vessels. The company is initially developing therapies for cardiovascular disease. Alteon has created a library of novel classes of compounds targeting the A.G.E. pathway. These include A.G.E. Crosslink Breakers, A.G.E. Formation Inhibitors and Glucose Lowering Agents. The Company's lead A.G.E. Crosslink Breaker, ALT-711, is being developed for the treatment of cardiovascular disorders including isolated systolic hypertension. The compound has successfully completed a Phase IIa clinical trial and will undergo further Phase II evaluation in 2001. Pimagedine, Alteon's lead A.G.E. Formation Inhibitor, is under evaluation for further clinical development. For more information on Alteon, visit the company's web site at www.alteonpharma.com.

Previous Forums
Date/Time		Forum
Jul 27 2001		San Francisco Biotechnology Stocks Forum
Feb 20 2001		BIO CEO & Investor Conference - Day One
Nov 28 2000		Virtual BioPharma Stocks Forum
Sep 12 1998		NY/NJ Biotechnology Stocks Forum

Market Assistant		PrecisionAlert
Earnings Data Annual Report		Enter your email address to receive alerts about this company